Article Versions Notes

Yun J, Ji YS, Jang GH, Lim SH, Kim SH, Kim CK, Bae SB, Won JH, Park SK. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy. Current Issues in Molecular Biology. 2021; 43(2):917-931. https://doi.org/10.3390/cimb43020065

Yun, Jina, Young Sok Ji, Geum Ha Jang, Sung Hee Lim, Se Hyung Kim, Chan Kyu Kim, Sang Byung Bae, Jong Ho Won, and Seong Kyu Park. 2021. "TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy" Current Issues in Molecular Biology 43, no. 2: 917-931. https://doi.org/10.3390/cimb43020065

Yun, J., Ji, Y. S., Jang, G. H., Lim, S. H., Kim, S. H., Kim, C. K., Bae, S. B., Won, J. H., & Park, S. K. (2021). TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy. Current Issues in Molecular Biology, 43(2), 917-931. https://doi.org/10.3390/cimb43020065